The company’s R&D expenditure will come down to 7-7.5 percent of sales after the disinvestment in Glenmark Lifesciences. It was virtually double, at 14.2 percent of sales, in FY 17-18
From violence risk assessment in emergency departments to connections between bipolar disorder and substance use disorders, here are highlights from the week in Psychiatric Times.
The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its developer, Enveric Biosciences (NASDAQ: ENVB).
Company to advance M107 into Phase 2 clinical development in gastroparesis based on feedback from Pre-IND meeting with FDARADNOR, Pa. (BUSINESS WIRE) Aclipse Therapeutics, and its subsidiary, Aclipse Two, Inc (“Aclipse”), an innovative biopharmaceutical company developing life-changing treatments for patients with.
A new agreement is poised to accelerate antibiotic access for tens of thousands of patients in regions with the highest rates of antimicrobial resistance (AMR). The Global Antibiotic Research & Development Partnership (GARDP) and India-based Orchid Pharma Ltd (Orchid) have signed a sublicense agreement to .